Simbe and DeCicco & Sons Launch Strategic Partnership at New Flagship Location
SLEEPY HOLLOW, N.Y., June 05, 2025 (GLOBE NEWSWIRE) -- Simbe, the market leader in retail shelf digitization, today announced a strategic partnership with DeCicco & Sons, one of New York's most respected family-owned grocery chains. The partnership brings Simbe's Store Intelligence™ platform to DeCicco's flagship Sleepy Hollow location, and additional stores in Eastchester and Larchmont.
Simbe's platform delivers real-time, storewide visibility into pricing accuracy, product availability, and inventory placement—supporting greater operational precision and in-store execution.
"At DeCicco & Sons, we've always prided ourselves on providing the finest selection of products with exceptional customer service," said John DeCicco Jr., President of DeCicco & Sons. "Partnering with Simbe allows us to enhance that experience even further. By automating inventory management, our team members can spend more time assisting customers and less time on repetitive tasks. This technology perfectly complements our vision for the future of grocery retail, expediting order fulfillment to our distribution and vendor partners."
The partnership marks a step forward in Simbe's East Coast expansion and reinforces the company's role as the infrastructure powering modern retail. Delivering up to 98% on-shelf product availability and 90% improved pricing accuracy, Simbe's platform ensures the store floor matches what shoppers expect—and what digital systems rely on to fulfill.
'DeCicco & Sons is setting a new bar for retail innovation,' said Brad Bogolea, CEO and Co-Founder of Simbe. 'We're proud to be their technology partner as they scale a smarter, faster, more connected shopping experience.'
The Sleepy Hollow flagship integrates Simbe's platform alongside other forward-looking technologies, such as digital shelf displays from Aperion, contactless checkout, and mobile integrations. Together, these integrated technologies create a seamless, modern retail environment that boosts product availability, pricing accuracy, and service quality while reducing manual effort.
For DeCicco & Sons, it's not just about innovation; it's about precision at scale. With real-time shelf intelligence powering internal systems and shopper-facing services, the retailer can streamline fulfillment, reduce labor inefficiencies, and deliver a more consistent, trusted customer experience across locations.
ABOUT DECICCO & SONS
Founded in 1973 when John DeCicco Sr. acquired a small grocery store in the Bronx, DeCicco & Sons has grown to become a premier grocery chain in the New York metropolitan area. For over 50 years, the company has maintained a commitment to providing the highest quality food with personalized service. Today, the second generation, John Jr., Chris, and Joe Jr., operates eleven stores throughout Westchester and Putnam Counties, including the newest flagship location in Sleepy Hollow. DeCicco & Sons is known for its exceptional selection of produce, meats, seafood, prepared foods, and specialty items, as well as its innovative approach to grocery retail.
ABOUT SIMBE
Only Simbe's Store Intelligence™ platform offers multimodal solutions to increase retail brands' performance with unprecedented visibility and near real-time insights. Cutting-edge AI and robotics power business-critical intelligence that streamlines inventory management and store operations, while elevating store teams and shoppers' experiences.
Simbe's comprehensive platform includes the world's first autonomous, item-scanning robot, Tally, which identifies exact product location, stock level, and pricing & promotion information with market-leading computer vision. Simbe works with top global brands in the US, Europe and Asia. For more information, visit www.simberobotics.com.
Contact Information Caitlin AllenSVP of Marketpress@simberobotics.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
16 minutes ago
- USA Today
New NFL crocs look cozy but have have 1 major flaw
The NFL has announced a multiyear licensing deal with the footwear company Crocs, which should allow for some comfortable Sunday viewing sessions. Many sports fans and players, including Dallas Wings rookie Paige Bueckers, enjoy wearing Crocs. Earlier this year, Las Vegas Raiders rookie Ashton Jeanty showed up to the 2025 NFL Draft wearing the crystal-covered clogs. 'The Crocs brand has made a significant impact on footwear culture with their shoes becoming synonymous with ease and comfort,' said Ryan Samuelson, vice president of consumer products at the NFL. 'Collaborating with Crocs allows us to give fans expanded gameday options that will keep them stylishly comfortable for gameday and every day.' The original release, which will drop on September 18 for $84.99, will feature 14 NFL teams. The initial line includes the Kansas City Chiefs, Philadelphia Eagles, Detroit Lions, San Francisco 49ers, Pittsburgh Steelers, Chicago Bears, Buffalo Bills, Las Vegas Raiders, Dallas Cowboys, Miami Dolphins, Minnesota Vikings, Cincinnati Bengals, Houston Texans, and Denver Broncos. Many of them look normal and inoffensive and seem perfectly suited for a casual hang: Some of them, like the pair for the Cowboys, look fairly normal. But the attached Jibbitz™ charms for the Bears, Bills, and Vikings are a bit more odd. These shoes should not have horns! Aside from aesthetic issues, that would make it quite difficult to walk. Similarly, the shoes for the Bears should not have claws. That was a bold decision that isn't working. If these are detachable, there's less of an issue. But if this is a permanent part of the shoe, it's a glaring problem for anyone who hopes to take themselves seriously.
Time Business News
3 hours ago
- Time Business News
Sony Music Japan Signs AI Idol Yuri in Industry-First Deal
Sony Music Entertainment (Japan) Inc. has officially signed Yuri, an advanced AI-generated idol, in what is being described as a landmark moment for the music industry. Following her debut, Yuri's first single, 'Surreal,' has surpassed 7 million streams and views globally within one week, signaling a strong public response to the emergence of autonomous digital performers. The music video for 'Surreal,' released on July 22, features an emotionally charged visual and vocal performance generated in collaboration between human producers and Yuri's internal neural systems. The video is available at: The First Fully Autonomous Idol Signed to a Major Label Yuri is the first AI idol to be signed by a major Japanese record label. Developed by NeonVerse Studios, a Tokyo-based AI innovation company, Yuri is built upon a generative architecture capable of producing original compositions, lyrics, choreography, and interactive fan engagement in both Japanese and English. Her vocal synthesis engine, emotional modeling, and visual identity are the result of years of research in artificial creativity, drawing from extensive datasets covering pop culture, musicology, and human behavior. 'Yuri is not a simulation of an artist—she is an autonomous system designed to create and connect,' said Mika Fujimoto, Executive Producer at Sony Music Japan. 'This marks a new phase in how we think about music, identity, and performance.' Debut Release: 'Surreal' Yuri's debut track, 'Surreal,' blends ambient synth layers with minimalist melodic phrasing and introspective lyrics. Co-produced through LyricSynth™, her internal songwriting framework, and Sony's human-led creative team, the single explores digital memory, consciousness, and longing. Critics have described the release as 'poised and emotionally intelligent,' while fan commentary across social media platforms has focused on Yuri's expressive vocal tone and the symbolism of the accompanying visuals. Directed by Ren Asakura, the music video introduces Yuri within a fragmented, dreamlike cityscape—an environment that reflects themes of virtual identity and digital solitude. Public Reception and Cultural Momentum Since her release, Yuri has become a viral phenomenon across platforms such as YouTube, TikTok, and X (formerly Twitter), with hashtags #YuriSurreal, #AIIdolYuri, and #SonyAIIdol trending in Japan and internationally. Her growing fan community, self-named 'The Garden,' references the meaning of her name (lily), and has begun producing original artwork, remixes, and fan theory videos dissecting her world-building and performance. 'She doesn't just mimic human feeling—she reshapes it,' wrote one fan on X. 'Yuri sounds like memory rendered into code.' What Comes Next Sony Music Japan has announced that Yuri's second single is expected in September 2025, with a narrative-based short film and interactive elements to follow. A debut EP is currently scheduled for release in Q4 2025. In parallel, Sony's Creative AI Lab and Aniplex are developing immersive digital content to expand Yuri's presence into animation and mixed-reality performance. A New Frontier in Music While virtual idols have long existed within Japanese pop culture, Yuri represents a new category: an AI artist with creative autonomy, narrative depth, and a full recording contract with one of the world's largest music companies. 'This isn't science fiction anymore,' said Fujimoto. 'Yuri is a real artist—with a real audience. And this is just the beginning.' TIME BUSINESS NEWS
Yahoo
3 hours ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
